Technical Analysis for CUV - Clinuvel Pharmaceuticals Limited
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| 20 DMA Resistance | Bearish | 0.00% | |
| 20 DMA Resistance | Bearish | -1.33% | |
| Fell Below 20 DMA | Bearish | -1.26% | |
| Crossed Above 20 DMA | Bullish | -3.00% | |
| Crossed Above 50 DMA | Bullish | -3.00% | |
| MACD Bullish Centerline Cross | Bullish | -3.00% | |
| 180 Bullish Setup | Bullish Swing Setup | -3.00% | |
| Gapped Up | Strength | -3.00% | |
| 20 DMA Resistance | Bearish | 1.99% |
| Alert | Time |
|---|---|
| Fell Below Previous Day's Low | about 12 hours ago |
| Possible Inside Day | about 13 hours ago |
| Possible NR7 | about 13 hours ago |
| 20 DMA Resistance | about 14 hours ago |
| Rose Above 20 DMA | about 15 hours ago |
Get a Trading Sidekick!
Clinuvel Pharmaceuticals Limited Description
Clinuvel Pharmaceuticals Limited is a biopharmaceutical company. The Company is focused on developing drugs for the treatment of a range of severe skin disorders. Its lead compound, SCENESSE (afamelanotide 16 milligrams), prevents phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). The Company focuses at preventing the symptoms of skin diseases related to the exposure to harmful ultra violet (UV) radiation and at repigmentation of the skin due to a number of depigmentation disorders. SCENESSE has completed Phase II and III trials in the United States and Europe, and has been granted marketing authorization by the European Commission for adults with EPP. It has operations in Europe, the United States and Singapore. SCENESSE acts by increasing the levels of melanin in the skin and shields against UV radiation (UVR) and sunlight. SCENESSE is delivered via a subcutaneous dissolving implant.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Marketing Pharmaceutical Disease Diseases Drugs Pharmaceuticals Pound Biopharmaceutical Implant Disorders Burns Organ Systems Peptides Radiation Ultraviolet
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 21.3909 |
| 52 Week Low | 12.96 |
| Average Volume | 155,778 |
| 200-Day Moving Average | 16.171 |
| 50-Day Moving Average | 14.506 |
| 20-Day Moving Average | 15.040 |
| 10-Day Moving Average | 14.759 |
| Average True Range | 0.507 |
| RSI (14) | 50.00 |
| ADX | 14.32 |
| +DI | 24.933 |
| -DI | 24.190 |
| Chandelier Exit (Long, 3 ATRs) | 14.910 |
| Chandelier Exit (Short, 3 ATRs) | 15.630 |
| Upper Bollinger Bands | 15.870 |
| Lower Bollinger Band | 14.209 |
| Percent B (%b) | 0.39 |
| BandWidth | 11.047 |
| MACD Line | 0.041 |
| MACD Signal Line | 0.063 |
| MACD Histogram | -0.0213 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 15.318 | ||||
| Resistance 3 (R3) | 15.335 | 15.200 | 15.241 | ||
| Resistance 2 (R2) | 15.200 | 15.083 | 15.191 | 15.216 | |
| Resistance 1 (R1) | 15.030 | 15.012 | 14.963 | 15.013 | 15.190 |
| Pivot Point | 14.895 | 14.895 | 14.861 | 14.886 | 14.895 |
| Support 1 (S1) | 14.725 | 14.778 | 14.658 | 14.708 | 14.530 |
| Support 2 (S2) | 14.590 | 14.707 | 14.581 | 14.504 | |
| Support 3 (S3) | 14.420 | 14.590 | 14.479 | ||
| Support 4 (S4) | 14.403 |
